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Abstract
Background: Constitutive activation of MEK1 (caMEK) can induce the oncogenic transformation
of normal intestinal epithelial cells. To define the genetic changes that occur during this process,
we used oligonucleotide microarrays to determine which genes are regulated following the
constitutive activation of MEK in normal intestinal epithelial cells.
Results: Microarray analysis was performed using Affymetrix GeneChip and total RNA from
doxycycline inducible RIEtiCAMEK cells in the presence or absence of doxycycline. MEK-activation
induced at least a three-fold difference in 115 gene transcripts (75 transcripts were up-regulated,
and 40 transcripts were down-regulated). To verify whether these mRNAs are indeed regulated
by the constitutive activation of MEK, RT-PCR analysis was performed using the samples from
caMEK expressing RIE cells (RIEcCAMEK cells) as well as RIEtiCAMEK cells. The altered
expression level of 69 gene transcripts was confirmed. Sixty-one of the differentially expressed
genes have previously been implicated in cellular transformation or tumorogenesis. For the
remaining 8 genes (or their human homolog), RT-PCR analysis was performed on RNA from
human colon cancer cell lines and matched normal and tumor colon cancer tissues from human
patients, revealing three novel targets (rat brain serine protease2, AMP deaminase 3, and cartilage
link protein 1).
Conclusion:  Following MEK-activation, many tumor-associated genes were found to have
significantly altered expression levels. However, we identified three genes that were differentially
expressed in caMEK cells and human colorectal cancers, which have not been previously linked to
cellular transformation or tumorogenesis.
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Background
Mitogen-activated protein kinases (MAPKs) are serine-
threonine kinases activated by phosphorylation of spe-
cific amino acids in response to extracellular stimuli and
have been shown to play an important role in tumorigen-
esis [1-8]. The first member of this family to be character-
ized was the extracellular signal-regulated protein kinase
(ERK), which is phosphorylated and activated by MAPK/
ERK kinase (MEK) [1,2]. The MEK-ERK signaling pathway
is one of the downstream targets of oncogenic mutations
in ras [1,2] and the increased activity of MEK has been
identified in many human malignancies, including color-
ectal cancer [9]. Constitutive activation of MEK1 signaling
can induce the oncogenic transformation of fibroblast
[10-12], kidney [13], mammary [14], and intestinal epi-
thelial cells [8,15]. We recently reported that the onco-
genic potential of MEK in intestinal epithelial cells was
mediated by cyclooxygenase-2 (COX-2) [8]. COX-2 and
its derived prostaglandins are also thought to be involved
in the development and progression of colorectal cancer
[16,17]. The MEK-ERK cascade has been reported to
induce increased tumor invasiveness [18,19], pro-cell
cycle properties [8,20], angiogenesis [21], anti-apoptosis
[8,22], and resistance to some anti-cancer agents [23,24].
However, the precise role of MEK-ERK signaling in intes-
tinal carcinogenesis remains unknown.
In the past few years, newly developed technologies such
as gene microarrays [25] have enabled the determination
of molecular differences between normal and trans-
formed cells at a genome-wide level. However, since most
of these analyses were performed using bulk tissue sam-
ples that are composed of multiple cell lineages, the spe-
cific roles of identified genes during tumorigenesis are still
under investigation. Therefore, the information obtained
from a single cell before and after activation of a key sign-
aling pathway during transformation may be a useful
strategy for identifying novel targets. We previously estab-
lished tetracycline regulated constitutively activated
MEK1 (caMEK) expressing normal rat intestinal epithelial
cells (RIEtiCAMEK cells), and reported that caMEK could
induce the transformation of RIE and IEC-6 cells [8]. To
clarify the oncogenic potential of MEK-ERK signaling and
to identify novel targets of colonic carcinogenesis, we
sought to determine the genes involved in caMEK-medi-
ated transformation by gene microarray and RT-PCR anal-
ysis.
Results
Microarray results from RIEtiCAMEK cells
Total RNA from RIEtiCAMEK cells with/without doxycy-
cline (DOX) following treatment with 5 mM sodium
butyrate (NaB) for 48 hours were submitted for microar-
ray analysis. RIEtiCAMEK cells express high levels of
caMEK upon removal of DOX from the culture media and
in the presence of NaB. One hundred-fifteen genes were
observed (75 genes showed increased expression, while
40 genes were down regulated) with at least a three-fold
difference in expression (data not shown).
Confirmation of microarray results by RT-PCR analysis
To confirm the differential expression of the genes
observed from the microarray results, RT-PCR analysis
was performed using gene-specific primers and RNA from
MEK-inducible RIEtiCAMEK cells in the presence of NaB.
Over 97% of all transcripts (113/115) observed by micro-
array were verified by RT-PCR analysis from the RIEti-
CAMEK cells (data not shown). In order to account for the
possibility that transcripts were altered by a histone
deacetylase (HDAC) inhibitor which could potentially
influence global gene expression [30,31], we also deter-
mined the gene profile of other caMEK and empty vector
transfected cells in the absence of NaB. Therefore, RT-PCR
analysis was performed on constitutively expressing
caMEK clones (RIEcCAMEK cells; clone DD13, DD14)
[8], as well as empty vector transfected cells (RIE-mock
cells) in the absence of NaB. We confirmed 69 genes with
altered transcription levels in both cell systems induced by
caMEK (Figure 1, 2). However, the altered expression of
46 genes was not confirmed in the second cell system.
Therefore, these 46 transcripts may not be regulated by
caMEK and are possibly influenced by a HDAC inhibitor.
The results from both cell systems indicated that 69 genes
may be true targets of MEK-activation in RIE cells. The
majority of these differentially expressed genes have pre-
viously been implicated in cellular transformation or
tumorigenesis, including TGF-α and cyclooxygenase-2
(up-regulated genes) as well as DOC-2/DAB2 (down-reg-
ulated gene).
Gene expression analysis in human colon cancers by RT-
PCR
From the results of above experiments, we searched
approximately 69 genes using PubMed (National Center
for Biotechnology Information) for their involvement in
cellular transformation or human cancer. We found that 8
genes (NPPB, PRSS22, CCR1, CTPCH1, P2RY2, AMPD3,
CRTL1, AKAP150) did not have clear involvement. We
focused on these 8 genes and performed RT-PCR analysis
using the samples from 5 human colon cancer cell lines
and human colon cancer tissues (tumor and correspond-
ing adjacent normal mucosa from individual patients).
Three novel targets were shown to have altered expression
levels (Figure 3A,B). Human tryptase-ε/PRSS22, which is
highly homologous to rat brain serine protease bsp2, and
adenosine monophosphate deaminase 3 (AMPD3) were
up-regulated in all 5 human colon cancer tissues com-
pared to the corresponding normal mucosa. These tran-
scripts were also expressed in several different colon
cancer cell lines (4 of 5 and 5 of 5 respectively). Con-Molecular Cancer 2006, 5:63 http://www.molecular-cancer.com/content/5/1/63
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Altered expression levels of caMEK-regulated genes involved in cell migration/invasion, cell adhesion, tumor suppression, anti- apoptosis, drug metabolism, and growth/proliferation Figure 1
Altered expression levels of caMEK-regulated genes involved in cell migration/invasion, cell adhesion, tumor suppression, anti-
apoptosis, drug metabolism, and growth/proliferation. The microarray results from caMEK expressing cells (DOX(-)) com-
pared to normal cells (DOX(+)) are expressed as fold difference ± S.D. Differentially expressed genes were verified through 
RT-PCR analysis. β-actin was used to indicate equal template in each lane.Molecular Cancer 2006, 5:63 http://www.molecular-cancer.com/content/5/1/63
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Altered expression levels of caMEK-regulated genes from transcription factor, signal transduction, metabolic, transportation,  cytoskeletal, and other pathways Figure 2
Altered expression levels of caMEK-regulated genes from transcription factor, signal transduction, metabolic, transportation, 
cytoskeletal, and other pathways. The microarray results from caMEK expressing cells (DOX(-)) compared to normal cells 
(DOX(+)) are expressed as fold difference ± S.D. Differentially expressed genes were verified through RT-PCR analysis. β-
actin was used to indicate equal template in each lane.Molecular Cancer 2006, 5:63 http://www.molecular-cancer.com/content/5/1/63
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versely, cartilage link protein 1 (CRTL1) was down-regu-
lated in all 5 human colon cancer tissues and was
expressed in only two of 5 colon cancer cell lines.
Discussion
Recently, we reported that caMEK signaling is highly
oncogenic and induces cellular transformation in rat
intestinal epithelial cells [8]. We now show,, through the
use of microarray analysis, that many genes associated
with cellular transformation have altered expression levels
following constitutive MEK activation. MEK-ERK signal-
ing is associated with cell migration, invasion, and metas-
tasis [18,19]. Our array results indicate that 10 transcripts
associated with cell migration (e.g. MMP10, MMP13, etc)
and adhesion (e.g. PTHLH, OPN, etc) have altered expres-
sion levels following MEK activation. Additionally, 7
genes known to possess tumor suppressor function (e.g.
GPC3/OCI-5, LOT1/PLAGL1/ZAC1, etc) were down-regu-
lated by MEK-activation. Furthermore, several genes that
possess anti-apoptotic or chemo-resistant properties were
over-expressed in caMEK expressing clones. The altered
expression of transcripts was also seen in genes that are
involved in growth and proliferation, transcription, signal
transduction, biosynthesis, and the cytoskeleton.
Together, this data supports our finding that MEK signal-
ing positively regulates transformation in intestinal epi-
thelial cells.
Among the most interesting findings, surface antigen
CD44, complement resistance factor CD55/Daf, and
secreted phosphoglycoprotein OPN, all of which are
known to be implicated in colorectal cancer [25-32], were
also up-regulated by caMEK. All of these results suggest
the importance of MEK signaling in the intestinal tumori-
genesis. Oncogenic transformation of rat intestinal epi-
thelial cells following MEK-activation may depend on the
balance between increased transcription of tumor-pro-
moting genes and reduced levels of tumor suppressor
genes.
We also have shown three transcripts that may be
involved in human colorectal cancer. Of particular inter-
est are the up-regulation of tryptase-ε/PRSS22 and
AMPD3, and the down-regulation of CRTL1. Tryptase-ε/
PRSS22 is a member of the chromosome 16p13.3 family
of human serine proteases that is preferentially expressed
by epithelial cells [36]. The tryptase-ε/PRSS22 gene is
expressed in the airways in a developmentally regulated
manner and is a major product of several different trans-
formed epithelial cell lines [36]. Malignant cells require a
range of proteolytic activities to enable growth, survival,
and expansion [37]. Tryptase-ε/PRSS22 may play a role in
this process. AMPD3 is one of the isoforms of the AMP
deaminase family, which converts AMP to IMP and is a
diverse and highly regulated enzyme that is a key compo-
RT-PCR analysis of human colon cancer tissue and cell lines Figure 3
RT-PCR analysis of human colon cancer tissue and cell lines. (A) RT-PCR analysis was performed on 5 paired normal 
and tumor human colon cancer tissues. T indicates tumor tissue and N indicates corresponding normal adjacent mucosa. 
Gene-specific primers for PCR were designed by MacVector 7 software depending on the information from GeneBank. Ampli-
cation of the right target DNA was confirmed by sequence analysis. β-actin was used as an internal control to confirm equal 
amount of the templates. (B) RT-PCR analysis was performed on 5 human colon cancer cell lines (HCT116, HT29, LS174T, 
CaCO2, LoVo) with the indicated primer sets.Molecular Cancer 2006, 5:63 http://www.molecular-cancer.com/content/5/1/63
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nent of the adenylate catabolic pathway [38]. This enzyme
serves to protect the cell against sharp decreases in the
adenylate energy charge by removing AMP generated
when the rate of utilization of ATP is suddenly increased
[39]. In cancer cells, a marked imbalance in the enzymic
pattern of purine metabolism is linked with transforma-
tion and/or tumor progression [40]. This enzymatic
change of purine metabolism seems to be present in trans-
formed intestinal epithelial cells. CRTL1 (also known as a
link protein) is a small glycoprotein of the extracellular
matrix that was originally identified for its role in stabiliz-
ing aggregates of aggrecan and hyaluronan in cartilage
[41]. In addition to being expressed in cartilage, CRTL1 is
also immunolocalized in several noncartilaginous tissues
[41]. A recent study has suggested that CRTL1 may be a
down-stream target of β-catenin in intestinal epithelial
cells, which has been implicated early in the progression
of colorectal epithelial cells to cancer [42]. Therefore, this
gene may also serve a role in preventing tumor formation
of intestinal cells. This is the first report which indicates
the involvement of these three genes in colorectal cancer.
Conclusion
Although a great body of evidence shows the importance
of Ras and its downstream signaling mediators (Raf-MEK-
ERK) on colorectal tumor development, the precise role of
MEK remains undefined. Our results show that several
genes previously known to be implicated in cellular trans-
formation or tumorigenesis were altered following consti-
tutive MEK activation in rat intestinal epithelial cells.
Therefore, the MEK-ERK cascade seems to play an impor-
tant role in intestinal transformation. Also, this is the first
report, which indicates the involvement of these three
genes in colorectal cancer. Some of the genes acting down-
stream of this signaling pathway may become useful
markers for detection or therapeutic targets for colorectal
cancer.
Methods
Cell lines and preparation of total RNA
The RIEtiCAMEK cells, RIEcCAMEK cells, and RIE-mock
cells have been previously described [8]. Human colon
cancer cell lines, HT29, CaCO2, LS174T, HCT116, and
LoVo cells were purchased from American Type Culture
Collection (ATCC). The cells were maintained in Eagle's
minimal essential medium (Invitrogen, Carlsbad, CA)
(CaCO2 and LS174T cells), McCoy 5A medium (Invitro-
gen) (HT29 and HCT116 cells) or Ham's F12 medium
(Invitrogen) (LoVo cells) with 10% heat-inactivated fetal
bovine serum (FBS) (Hyclone Laboratories, Logan, UT),
and 2 mM L-glutamine. Total RNAs were isolated from
each cells using TRIzol reagent (Invitrogen), and were
purified by the RNeasy mini kit (Qiagen, Valencia, CA)
following treatment with DNase I.
Analysis of gene expression by microarray
Total RNAs were isolated from RIEtiCAMEK cells with/
without 2 µg/ml doxycycline (DOX) (BD Bioscience, Palo
Alto, CA) following treatment with a histone deacetylase
(HDAC) inhibitor (5 mM sodium butyrate (NaB) (Sigma,
St.Louis, MO). The HDAC inhibitor can enhance trans-
gene expression under the control of the CMV promoter
[26-28], and induces nearly a 3000-fold increase of trans-
gene expression in the cells (data not shown). Samples
were sent to Genome Explorations, Inc. (Menphis, TN),
where the RNA samples were converted to biotinylated
cRNA and hybridized to the Affymetrix (Santa Clara, CA)
Rat Genome U34A GeneChip array according to manufac-
turer's directions. The scanned images were analyzed
using Microarray software (Affymetrix). Sample loading
and variations in staining were standardized by scaling
the average of the fluorescent intensities of all genes on an
array to constant target intensity (2500) for all arrays
used. The expression data were analyzed as previously
described [29]. The signal intensity for each gene was cal-
culated as the average intensity difference, represented by
[µ(PM – MM)/(number of probe pairs)], where PM and
MM denote perfect-match and mismatch probes. The
analysis was performed twice (biological and technical
replicates).
Analysis of gene expression by RT-PCR
Single-stranded cDNA was synthesized using oligo-(dT)
primer and Superscript II reverse transcriptase (Invitro-
gen). PCR reactions were done in 50 µL volumes and
amplified for 2 minutes at 94°C for initial denaturation,
followed by 20–30 cycles at 94°C for 30 seconds, 50–
64°C for 30 seconds, and 72°C for 1 minute (the condi-
tions of reaction cycles and annealing temperatures were
optimized for each individual pair of primers). PCR prod-
ucts were separated on 1.6–2.0% agarose gels and visual-
ized by ethidium bromide staining. Amplication of the
correct target DNA was confirmed by sequence analysis.
Gene-specific primers for PCR products were designed by
MacVector 7 software (Accelrys, San Diego, CA) using
information from GenBank (NCBI). Gene function anno-
tations were obtained from the Affymetrix web site and/or
GenBank. RT-PCR analysis was also performed with sam-
ples from human colon cancer cell lines and human colon
normal and tumor matched cDNA pair panels (BD Bio-
science). β-actin was used as an internal control to con-
firm equal amounts of template.
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